Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Hookipa Pharma Inc (NQ: HOOK )

0.8590 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.8590
Bid (Size) 0.8000 (5)
Ask (Size) 0.8576 (7)
Prev. Close 0.8590
Today's Range 0.8590 - 0.8590
52wk Range 0.4100 - 1.140
Shares Outstanding 21,588,756
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Penny Stock Sleepers: 7 Under-the-Radar Gems Ready to Launch
Penny stocks to buy understandably offers many enticing attributes, not least of which is the potential for tremendous returns. 
Via InvestorPlace
HOOK Stock Earnings: HOOKIPA Pharma Beats EPS, Beats Revenue for Q1 2024
HOOK stock results show that HOOKIPA Pharma beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace

Performance

YTD
+3.49%
+3.49%
1 Month
+21.50%
+21.50%
3 Month
+29.17%
+29.17%
6 Month
+69.43%
+69.43%
1 Year
-19.72%
-19.72%

More News

Read More
HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Breaking Down HOOKIPA Pharma: 4 Analysts Share Their Views
Via Benzinga
Stocks Creating Buzz Look Now: VTAK, AMST, HOOK, MULN, KAVL
Via AB Newswire
Topics Artificial Intelligence
Exposures Artificial Intelligence
HOOKIPA Pharma: Q4 Earnings Insights
Via Benzinga
HOOKIPA Pharma Announces Pivotal Phase 2/3 Trial Design for HB-200 in Combination with Pembrolizumab
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Why Is Penny Stock HOOKIPA Pharma Trading Higher On Wednesday?
Via Benzinga
Exposures Product Safety
HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma Announces Grant of Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Roche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
Via Benzinga
HOOKIPA Pharma to Host Investor Call on HB-200 and Planned Path to Registration
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOK Stock Earnings: HOOKIPA Pharma Misses EPS, Beats Revenue for Q4 2023
Via InvestorPlace
HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
From HOOKIPA Pharma Inc.
Via GlobeNewswire
HOOKIPA Pharma to Participate in Leerink Partners Global Biopharma Conference
From HOOKIPA Pharma Inc.
Via GlobeNewswire
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Roche Walks Away From HOOKIPA Pharma-Partnered KRAS-Focused Cancer Deal
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs
From HOOKIPA Pharma Inc.
Via GlobeNewswire
AbbVie, Arch Capital, Gilead Sciences And A Telecom Giant On CNBC's 'Final Trades'
Via Benzinga
HOOKIPA Pharma Appoints Mark Winderlich as Chief Development Officer to Lead Clinical Research and Development Organization
From HOOKIPA Pharma Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.